News

Joel Citron, chairman of the OXiGENE board of directors, said: “The board has complete confidence in John’s ability to lead OXiGENE through its next stages of development, to

StemCor will develop the system for Hospira, and Hospira will manage the clinical trial program, leading to commercialization. The system has 510(k) clearance from the FDA and CE

Barr has filed its abbreviated new drug application (ANDA) containing a paragraph IV certification for a generic version of Opana ER with the FDA, and following receipt of

The technology, identified at the National Institutes of Health’s (NIH) National Heart, Blood and Lung Institute, shows that nitrite, which is converted by the body into nitric oxide,

Under the terms of the collaboration, Bayer HealthCare receives exclusive worldwide rights to develop anticancer compounds to the target using ImmunoGen’s maytansinoid cell-killing agents and linker technology. Bayer

Under the terms of this agreement, NxStage will supply the Streamline airless blood tubing set as well as MasterGuard and other products to Renal Advantage’s dialysis center network.

Early Lyme disease research has resulted in three significant findings. First, the study team has identified and synthesized ‘key’ peptides that are predicted to have high binding affinity

The novel dressing features a polymer-based core that could help change the way clinicians manage heavily exuding wounds, currently a significant issue in wound care. Ed Quilty, CEO

Mr Johnson has agreed to serve as a consultant to the company until March 31, 2009, the end of the company’s current fiscal year, to assist with transition